MVA regression model for CV-AEs and AT-AEs after starting TKI therapy
| . | Full model . | |
|---|---|---|
| IRR (95% CI) . | P* . | |
| CV-AEs | ||
| TKI type | ||
| IM400 (reference) | ||
| IM800 | 0.67 (0.44-1.01) | .054 |
| Nilotinib | 0.94 (0.59-1.49) | .786 |
| Dasatinib | 0.76 (0.47-1.22) | .261 |
| Ponatinib | 4.62 (2.74-7.79) | <.0001 |
| Age, y | 1.03 (1.02-1.04) | <.0001 |
| Serum albumin, g/dL | 0.57 (0.42-0.78) | <.0001 |
| Prior hypertension | ||
| No | ||
| Yes | 1.53 (1.15-2.02) | .003 |
| BMI ≥30, kg/m2 | ||
| No | ||
| Yes | 1.59 (1.21-2.09) | .001 |
| Risk factors | ||
| 1 | 1.58 (1.04-2.38) | .030 |
| 2 | 2.23 (1.49-3.35) | <.0001 |
| ≥3 | 3.17 (2.04-4.91) | <.0001 |
| AT-AEs | ||
| TKI type | ||
| IM400 (reference) | ||
| IM800 | 0.33 (0.10-1.03) | .057 |
| Nilotinib | 1.49 (0.48-4.58) | .487 |
| Dasatinib | 2.08 (0.71-6.12) | .184 |
| Ponatinib | 6.38 (1.87-21.80) | .003 |
| Age, y | 1.06 (1.03-1.09) | <.0001 |
| Serum albumin, g/dL | 0.42 (0.20-0.89) | .023 |
| Risk factors | ||
| 1 | 1.95 (0.62-6.11) | .25 |
| 2 | 3.02 (1.00-9.12) | .05 |
| ≥3 | 6.82 (2.23-20.88) | <.0001 |
| . | Full model . | |
|---|---|---|
| IRR (95% CI) . | P* . | |
| CV-AEs | ||
| TKI type | ||
| IM400 (reference) | ||
| IM800 | 0.67 (0.44-1.01) | .054 |
| Nilotinib | 0.94 (0.59-1.49) | .786 |
| Dasatinib | 0.76 (0.47-1.22) | .261 |
| Ponatinib | 4.62 (2.74-7.79) | <.0001 |
| Age, y | 1.03 (1.02-1.04) | <.0001 |
| Serum albumin, g/dL | 0.57 (0.42-0.78) | <.0001 |
| Prior hypertension | ||
| No | ||
| Yes | 1.53 (1.15-2.02) | .003 |
| BMI ≥30, kg/m2 | ||
| No | ||
| Yes | 1.59 (1.21-2.09) | .001 |
| Risk factors | ||
| 1 | 1.58 (1.04-2.38) | .030 |
| 2 | 2.23 (1.49-3.35) | <.0001 |
| ≥3 | 3.17 (2.04-4.91) | <.0001 |
| AT-AEs | ||
| TKI type | ||
| IM400 (reference) | ||
| IM800 | 0.33 (0.10-1.03) | .057 |
| Nilotinib | 1.49 (0.48-4.58) | .487 |
| Dasatinib | 2.08 (0.71-6.12) | .184 |
| Ponatinib | 6.38 (1.87-21.80) | .003 |
| Age, y | 1.06 (1.03-1.09) | <.0001 |
| Serum albumin, g/dL | 0.42 (0.20-0.89) | .023 |
| Risk factors | ||
| 1 | 1.95 (0.62-6.11) | .25 |
| 2 | 3.02 (1.00-9.12) | .05 |
| ≥3 | 6.82 (2.23-20.88) | <.0001 |
Analysis showing MVA Poisson regression models for new-onset vascular AEs (CV-AEs and AT-AEs) after starting TKI therapy.
Bold indicates significant P values (P < .05).